CN119173275A - Glp-1多肽的前药及其用途 - Google Patents

Glp-1多肽的前药及其用途 Download PDF

Info

Publication number
CN119173275A
CN119173275A CN202380039160.4A CN202380039160A CN119173275A CN 119173275 A CN119173275 A CN 119173275A CN 202380039160 A CN202380039160 A CN 202380039160A CN 119173275 A CN119173275 A CN 119173275A
Authority
CN
China
Prior art keywords
formula
glp
compound
compound according
life
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380039160.4A
Other languages
English (en)
Chinese (zh)
Inventor
B·普雷姆德吉
J·F·劳
C·M·乔根森
L·利克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN119173275A publication Critical patent/CN119173275A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202380039160.4A 2022-05-10 2023-05-09 Glp-1多肽的前药及其用途 Pending CN119173275A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22172545.0 2022-05-10
EP22172545 2022-05-10
PCT/EP2023/062208 WO2023217744A1 (en) 2022-05-10 2023-05-09 Prodrugs of glp-1 polypeptide and uses thereof

Publications (1)

Publication Number Publication Date
CN119173275A true CN119173275A (zh) 2024-12-20

Family

ID=81940650

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380039160.4A Pending CN119173275A (zh) 2022-05-10 2023-05-09 Glp-1多肽的前药及其用途

Country Status (7)

Country Link
US (1) US20250304645A1 (https=)
EP (1) EP4522220A1 (https=)
JP (1) JP2025517672A (https=)
CN (1) CN119173275A (https=)
AR (1) AR129270A1 (https=)
TW (1) TW202346324A (https=)
WO (1) WO2023217744A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025092778A1 (zh) * 2023-10-31 2025-05-08 深圳信立泰药业股份有限公司 Glp-1化合物及其制备方法与应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238671B2 (en) * 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
WO2010080605A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Dipeptide linked medicinal agents
ES2401965T3 (es) 2009-02-19 2013-04-25 Novo Nordisk A/S Modificación de Factor VIII
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
JP6039569B2 (ja) 2010-11-09 2016-12-07 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
US9452225B2 (en) 2012-03-01 2016-09-27 Novo Nordisk A/S GLP-1 prodrugs
JP2016521253A (ja) 2013-03-15 2016-07-21 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 持続性作用を有するプロドラッグ
JP6701208B2 (ja) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 脂質化アミド系インスリンプロドラッグ
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物

Also Published As

Publication number Publication date
WO2023217744A1 (en) 2023-11-16
US20250304645A1 (en) 2025-10-02
AR129270A1 (es) 2024-08-07
TW202346324A (zh) 2023-12-01
JP2025517672A (ja) 2025-06-10
EP4522220A1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
TWI850599B (zh) 前藥及其用途
US10604555B2 (en) GIP derivatives and uses thereof
US11242373B2 (en) GLP-1 analogues
CN108026157B (zh) 新型胰岛素衍生物及其医学用途
JP2007537141A (ja) 新規なｇｌｐ−１化合物
KR20230042019A (ko) Glp-1 및 gip 수용체 공동-작용제
KR102704620B1 (ko) 프로드러그 및 이의 용도
CN116490212A (zh) Glp-1前药及其用途
CN102076353A (zh) 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽
US20250304645A1 (en) Prodrugs of GLP-1 Polypeptide and Uses Thereof
CN108368163A (zh) 新型胰岛素衍生物及其医学用途
CA3195872A1 (en) Glp-1 prodrugs and uses hereof
US12616739B2 (en) GLP-1 prodrugs and uses thereof
CN118632867A (zh) Glp-1/gip受体共激动剂前药及其用途
EA049274B1 (ru) Новые аналоги glp-1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination